KevinCWoodMD

PubMed

• 13 citations
  A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
  Tanguy Y. Seiwert, Sara Kochanny, Kevin Wood, Francis P. Worden, Douglas Adkins
  Cancer. 2020-07-15
• 25 citations
  Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer
  Shalin Shah, Kevin Wood, Brian W. Labadie, Brian Won, Ryan J. Brisson
  Oncotarget. 2018-01-12
• 11 citations
  A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients
  Alana Dikopf, Kevin Wood, Ravi Salgia
  Expert Opinion on Drug Safety. 2015-02-18

Journal Articles

• Reply to "KRAS in non-small cell lung cancer: What about oncogenic addiction and EGFR tyrosine kinase inhibitors?"  
  Wood K, Hensing T, Salgia R, JAMA Oncology, 1/21/2016
• RAS in Non-Small Cell Lung Cancer-Towards Precision Medicine and Therapeutics  
  Wood K, Hensing T,Malik R, Salgia R, JAMA Oncology, 1/1/2016
• Fractionated Stem Cell Infusions for Patients with Plasma Cell Myeloma Undergoing Autologous Hematopoietic Cell Transplantation  
  Landau H, Wood K, Chung D, et al, Leukemia and Lymphoma, 1/1/2016
• A safety assessment of crizotinib in the treatment of ALK-positive NSCLC patients  
  Dikopf A, Wood K, Salgia R, Expert Opin Drug Saf, 1/1/2015
• Join now to see all

Abstracts/Posters

• Clinical Characteristics of Acquired Resistance with anti-PD-1/PD-L1 in NSCLC.
  Wood K, Hensing T, Patel J, IASCL Chicago Conference, Chicago, IL, 1/1/2016
• Concurrent EGFR and ALK mutations in KRAS-mutant adenocarcinomas and their clinical behavior.
  Wood K, Hensing, T, Vokes E, Salgia R, IASCL World Conference, Denver, Co, 1/1/2015
• Relationship of KRAS mutations with EGFR and ALK in non-small cell lung cancer.
  Wood K, Hensing, T, Vokes E, Salgia R, IASCL American Conference, Santa Monica, 1/1/2015
• Improving Utilization of Interpreter Services by Medicine Admitting Housestaff.
  Mullally J, Wood K, Bao G, Bender M, Gingras L, Goetz C, Kyi C, Nicewarner H, Schneider Y, Clara Tow C, Lee J, 2014 Integrating Quality Improvement Meeting: Increasing Value and Educating for Quality, Chicago, IL, 1/1/2014
• PET/CT evaluation as a prognostic indicator in relapsed or refractory multiple myeloma.
  Rossi A, Wood K, Niesvizky, R, ASH, 1/1/2013
• Fractionated stem cell infusions for patients with multiple myeloma undergoing autologous stem cell transplant.
  Wood K, Landau H, Giralt, Sergio; et al, American Society for Blood and Bone Marrow Transplant, Salt Lake City, UT, 1/1/2013
• Join now to see all

Lectures

• "Fractionated Stem Cell Infusions for Multiple Myeloma patients undergoing autologous stem cell transplant" 
  1/1/2014

Other

• RAS Mutations in NSCLC. 
  Wood K, Oncology Practice MD-IQ Quiz (online)
  1/2/2016